Story

Compass Pathways Targets Q4 2026 for Psilocybin Therapy FDA Submission

ENTHMSVIIDZHZH-TWJAKOHI
Aug 11, 20262 min read
Compass Pathways Targets Q4 2026 for Psilocybin Therapy FDA Submission
Text size
Background

Compass Pathways (CMPS) is on track to complete its New Drug Application (NDA) with the U.S. Food and Drug Administration for its psilocybin-based therapy, COMP360, in the fourth quarter of 2026. The submission for treatment-resistant depression (TRD) follows two successful Phase 3 trials, positioning the company for a potential commercial launch in the first half of 2027, which would mark a major milestone for psychedelic medicine.

Clinical Data and Regulatory Path

The company's rolling NDA submission is supported by statistically significant results from its late-stage clinical program. According to the source material, the trials demonstrated a meaningful reduction in depression symptoms.

  • COMP005 Trial: This study involving 258 patients showed a 3.6-point reduction on the Montgomery-Åsberg Depression Rating Scale (MADRS) at week six (p<0.001).
  • COMP006 Trial: The larger trial with 581 patients showed a 3.8-point MADRS reduction over the same period (p<0.001).

COMP360 has received a Breakthrough Therapy designation from the FDA, which could potentially shorten the agency's review timeline. The FDA has also recently finalized guidance for psychedelic drug development, signaling institutional engagement with the emerging therapeutic class.

DEA Rescheduling Remains a Key Hurdle

Sample IUX Markets – In-articleAd

Despite positive clinical data and a clear path with the FDA, the most significant uncertainty for Compass Pathways is the required rescheduling of psilocybin by the Drug Enforcement Administration (DEA). Psilocybin is currently a Schedule I controlled substance, a classification for drugs with no accepted medical use and high abuse potential. For COMP360 to be prescribed, the DEA must move it to a lower schedule.

While the rescheduling of medical cannabis to Schedule III in April 2026 set a precedent, moving a classic psychedelic to a less restrictive category would be a landmark decision. This step remains a major variable that could potentially delay the therapy's launch by 6-12 months even after securing FDA approval, according to the source.

Commercial and Financial Outlook

If approved and rescheduled, COMP360 would target a substantial market of approximately 4 million U.S. patients with treatment-resistant depression. Analyst revenue estimates cited in the source project a steep ramp-up, from $47.2 million in 2027 to $219.7 million in 2028, with peak annual sales potentially reaching $2.3 billion.

Strategically, the company announced a partnership with the Department of Veterans Affairs on August 6, 2026, to study COMP360 in veterans, potentially opening a key government payer channel. Financially, Compass reported $433 million in cash, but a mixed shelf offering filed on August 4, 2026, signals that it may seek additional capital to fund its expensive commercialization build-out.

Read next

More on Stocks
Back to latest news

LATEST